The AIM-listed global cell-based medicines and life sciences company said its revenue for the year to 31 December 2017 was US$14.0mln, up from US$12.3mln a year earlier, with gross margins unchanged at 90%
Original Article: MaxCyte reports strong growth in cash and total assets in 2017 as revenues increase by 14%